› 4cni

X-ray diffraction
2.2Å resolution

Crystal structure of the Fab portion of Olokizumab in complex with IL- 6

Released:
DOI: 10.2210/pdb4cni/pdb
Model geometry
Fit model/data
PDB entry 4cni coloured by chain, front view.
PDB entry 4cni coloured by chain, side view.
PDB entry 4cni coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A
OpenAccess logo MAbs 6 774-82 (2014)
PMID: 24670876

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-209241 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
OLOKIZUMAB HEAVY CHAIN, FAB PORTION Chains: A, H
Molecule details ›
Chains: A, H
Length: 220 amino acids
Theoretical weight: 23.94 KDa
Source organism: Homo sapiens
Expression system: Cricetulus griseus
Structure domains: Immunoglobulins
OLOKIZUMAB LIGHT CHAIN, FAB PORTION Chains: B, L
Molecule details ›
Chains: B, L
Length: 214 amino acids
Theoretical weight: 23.28 KDa
Source organism: Homo sapiens
Expression system: Cricetulus griseus
Structure domains: Immunoglobulins
Interleukin-6 Chains: C, D

Ligands and Environments

2 bound ligands:
Ligand TAM 2 x TAM
Ligand SO4 5 x SO4
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: DIAMOND BEAMLINE I02
Spacegroup: P6
Unit cell:
a: 241.988Å b: 241.988Å c: 76.591Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.178 0.176 0.215
Expression systems:
  • Cricetulus griseus
  • Escherichia coli

Quick links

Citations

22 review citations

IL-6 as a keystone cytokine in health and disease.
Hunter et al. (2015)
21 more

36 mentions without citation

Druggable targets and therapeutic development for COVID-19.
Duan et al. (2022)
35 more

PDB-REDO

The sliders below show the change in model quality between original PDB entry and the PDB-REDO entry

Model Geometry
 
 
Data not available
DNA/RNA Geometry
 
 
Data not available
Fit model/data
 
 
Data not available
PDB-REDO